Back to search results

Understanding Young Onset Colorectal Cancer (YOCRC)

This study aims to better understand colorectal cancer that affects younger individuals (YOCRC). Researchers will collect blood, tissue, and stool samples, along with health information, from people with YOCRC and healthy individuals. This information will be used to create a database. The main goal is to analyze the genetic makeup of tissue samples over three years to learn more about this condition. You may be able to join if you are between 18 and 49 years old and have been diagnosed with colorectal adenocarcinoma. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 160 participants. It will include both individuals with colorectal cancer and healthy people.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Tissue samples will be analyzed at 3 years, which may indicate a follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05568420

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Active, Not Recruiting
Not specifiedAges 18–49Observational
Memorial Sloan Kettering Cancer Center
~41 participants
Updated 2026-08-20 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
genomic analysis of tissue
Measured over 3 years

Conditions

Colorectal Cancer

Explore related trials

Colorectal Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Andrea Cercek, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-49 years old
Histological or cytological diagnosis of colorectal adenocarcinoma
Planned CRC resection biopsy, or colonoscopy ,including surveillance colonoscopies and/or have already undergone prior surgical resection, with tissue, including normal colonic mucosae distant from the malignant tumor (only patients providing tissue sample)
Enrollment in IRB# 20-315, Young Onset Gastrointestinal Cancer Prospective Registry (Andrea Cercek, PI)
18-49 years old at time of diagnosis
Scheduled for standard-of-care colonoscopy at MSK
Underwent surgical resection of a traumatic injury to the colon at Shaare Zedek Medical Center (SZMC)

Exclusion

CRC Cohort:
Antibiotic use within 6 months of collection of stool for gut microbiome analysis s (only patients providing stool sample)
Known inherited cancer susceptibility gene
History of inflammatory bowel disease
Antibiotic use within 6 months of collection of stool for gut microbiome analysis (only patients providing stool sample)
History of or prior treatment for cancer ≤ 5 years prior to registration. Exceptions include non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix.
Colonoscopy for indications of IBD, anemia and/or genetic predisposition (only patients providing tissue sample).

What this trial measures

  • genomic analysis of tissue3 years

    For the genomic analyses, we will perform whole exome sequencing, MSK-IMPACT DNA-methylation and RNA assays of normal colonic mucosa and tumor. Other genomic analysis may be performed depending on the results of the initial analysis developments in this field. We will compare normal mucosa plus tumor in YOCRC vs normal mucosa in controls (using biopsies collected during outpatient colonoscopies not associated with hospitalizations)